MedPal AI (MPAL) has reported a record month of pharmacy activity, with March 2026 dispensing volumes reaching new highs and driving annualised revenues beyond £5 million.
The company said its wholly owned subsidiary, MedPal Limited, dispensed 41,600 prescription items in March, up 27.5% month on month and the highest level since operations began. Meanwhile, total items dispensed since launch in October 2025 have reached about 200,000, highlighting strong and sustained demand.
The rapid scale-up from zero volumes five months ago underscores the strength of MedPal’s automated pharmacy platform. As a result, the business is now generating annualised turnover in excess of £5 million, supported by continued growth across both NHS Distance Selling Pharmacy services and private prescriptions via MedPal.clinic.
In addition, March gross margins exceeded 34%, reflecting the benefits of the company’s technology-led cost base. The board noted that significant capacity remains within its automated infrastructure, providing scope for further volume growth without a corresponding increase in costs.
Looking ahead, MedPal expects continued momentum driven by rising NHS patient adoption and strong demand for GLP-1 weight-loss treatments through MedPal.clinic. Meanwhile, the company’s AI-powered triage and zero-cost consultation model is expected to support further expansion in the UK obesity treatment market.
MedPal AI’s Chief Executive Officer Jason Drummond said: “Dispatching over 41,000 items in March, our highest ever monthly total, is a landmark moment. In just five months, we have scaled from zero to an annualised pharmacy revenue run rate exceeding £5 million, and we have done this while delivering a gross margin of over 34% in March. This extraordinary rate of growth demonstrates the power of our vertically integrated, AI-driven model.
“Our technology-led cost structure means that as dispensing volumes grow, fixed costs are spread over a larger revenue base, driving further margin improvement. The traditional pharmacy model is being disrupted, and MedPal is leading that disruption. We look forward to updating the market on continued progress.”
View from Vox
MedPal AI’s latest update highlights a business scaling quickly with clear operational leverage. Strong volume growth, combined with margins above 34%, suggests the model is already proving efficient. Going forward, continued uptake in NHS services and demand for weight-loss treatments could provide further upside as the company utilises its existing infrastructure more fully.